hackint0sh/New-Dataset huggingface dataset:
Observation items and detection time: 1. During the screening period, the following data were collected: age, nationality, place of residence, education, occupation, height, weight, waist circumference, disease history, drug use history, drinking, smoking, normal water intake, urine volume, urine color and uric acid value. 2. Pre-test data: drinking water, urination, diet, psychological investigation, blood uric acid, blood biochemistry, routine blood routine, urine routine, uric acid, urine osmotic pressure, systolic blood pressure, diastolic blood pressure, heart rate, frequency of gout attack, whether to take urico-lowering drugs, whether to take other drugs that affect uric acid. 3. After the test: Fasting blood uric acid was monitored on the 2nd, 4th, 6th, 8th, 10th and 14th day respectively; Urge patients to record water diary and urination diary every day. At the end of the experiment, blood uric acid, blood biochemistry, blood routine, urine routine, urine uric acid, urine osmotic pressure, systolic blood pressure, diastolic blood pressure and heart rate were tested again. Safety assessment indicators: edema, gastrointestinal discomfort, electrolytes, blood pressure, heart rate. conditions: Hyperuricemia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 88 type: ESTIMATED name: Drink water measure: Blood uric acid change sex: MALE minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Xijing Hospital status: RECRUITING city: Xi'an state: Shanxi zip: 710032 country: China name: Li Peng role: CONTACT phone: 029-84771794 email: XJYYLLWYH@163.com lat: 34.25833 lon: 108.92861 hasResults: False
nctId: NCT06315530 id: sh12053 briefTitle: Effect of Telitacicept on Antibody Titers in Primary APS Patients overallStatus: RECRUITING date: 2023-01-01 date: 2025-12-31 date: 2026-12-31 date: 2024-03-18 date: 2024-03-18 name: Ruijin Hospital class: OTHER briefSummary: The purpose of this study is to evaluate the regulatory effect of Telitacicept on antibody titers in primary antiphospholipid syndrome patients carrying high-risk antiphospholipid antibody profiles. conditions: Antiphospholipid Syndrome (APS) studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Telitacicept name: SOC measure: The proportion of patients with decreased aPL titer at week 48 of treatment measure: new thrombotic event measure: Effects of Telitacicept on the genotype, phenotype, and functional heterogeneity of T and B cells measure: The incidence and severity of adverse events sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ruijin Hospital status: RECRUITING city: Shanghai state: Shanghai zip: 200025 country: China role: CONTACT phone: 0086-0021-64370045 name: Chengde Yang, Dr role: PRINCIPAL_INVESTIGATOR name: Hui Shi, Dr role: SUB_INVESTIGATOR lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06315517 id: AU24 id: 1792-23P type: OTHER_GRANT domain: The Dairy Alliance briefTitle: Double Crossover Casein Type Tolerance Trial overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-08 date: 2024-12 date: 2024-03-18 date: 2024-04-05 name: Auburn University class: OTHER briefSummary: The investigators will recruit 45 fluid milk avoiding adults to participate in a five-week double-blind, double-crossover study in which the physiological responses to increasing doses of lactose-free (A1-rich milk), A2 milk, and lactose-free A2 milk will be explored. conditions: Dairy Intolerance conditions: Healthy Adults studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Randomized controlled, double-blinded, double-crossover trial primaryPurpose: OTHER masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 45 type: ESTIMATED name: Conventional lactose-free cow's milk name: Nonconventional (A2) cow's milk name: Nonconventional (A2) lactose-free cow's milk measure: Gastrointestinal Distress Scores measure: Breath Hydrogen (ppm) measure: Breath Methane (ppm) measure: Blood Glucose (mg/dl) measure: Stool microbiome composition measure: Stool Beta-casomorphin-7 (BCM-7) measure: Stool intestinal fatty acid binding protein (I-FABP) sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Auburn University city: Auburn state: Alabama zip: 36849 country: United States name: Andrew D Frugé, PhD role: CONTACT lat: 32.60986 lon: -85.48078 hasResults: False
nctId: NCT06315504 id: Nephrotic Syndrome Cohort briefTitle: Circulating Factors in Nephrotic Syndrome overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2034-04-01 date: 2034-04-01 date: 2024-03-18 date: 2024-03-19 name: Iain Bressendorff class: OTHER briefSummary: A prospective observational study to investigate the treatment-associated changes of circulating factors associated with glomerular diseases among patients with de novo nephrotic syndrome admitted to hospital for a kidney biopsy. conditions: Nephrotic Syndrome conditions: Membranous Nephropathy conditions: Minimal Change Disease conditions: Primary Focal Segmental Glomerulosclerosis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 104 type: ESTIMATED name: Observation measure: levels of anti-nephrin in blood by ELISA measure: changes in auto-antibodies in blood associated with membranous nephropathy sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06315491 id: CBX-12-201 briefTitle: A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2026-04 date: 2026-04 date: 2024-03-18 date: 2024-03-18 name: Cybrexa Therapeutics class: INDUSTRY briefSummary: The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days. conditions: Platinum-resistant Ovarian Cancer conditions: Refractory Ovarian Carcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: CBX-12 measure: Percentage of Subjects With Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)] measure: Incidence of Subjects With Treatment Emergent Adverse Events (TEAEs) measure: Median Duration of Response (DoR) measure: Progression-Free Survival (PFS) measure: Plasma levels of CBX-12 (AUC0-24hr) measure: Plasma levels of CBX-12 (Cmax) measure: Plasma levels of CBX-12 (Tmax) measure: Plasma levels of CBX-12 (T1/2) measure: Plasma levels of Exatecan (AUC0-24hr) measure: Plasma levels of Exatecan (Cmax) measure: Plasma levels of Exatecan (Tmax) measure: Plasma levels of Exatecan (T1/2) sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06315478 id: Hybrid regimen for H.pylori briefTitle: Safety and Efficacy of Triple and Quadruple Regimens as First Line Therapy for Management of Helicobacter Pylori Infection in Egyptians overallStatus: COMPLETED date: 2021-02-01 date: 2021-03-16 date: 2021-11-01 date: 2024-03-18 date: 2024-03-18 name: Helwan University class: OTHER briefSummary: Our study aimed to investigate the efficacy and safety of hybrid regimen as a first line therapy for H. pylori eradication compared to triple and quadruple regimens in attempt to overcome antibiotic resistance conditions: H.Pylori Infection studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 60 type: ACTUAL name: Omeprazole 20 MG Oral Tablet name: Amoxicillin 500Mg Tab name: Clarithromycin 500Mg Tab measure: stool antigen retest sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Badr hospital city: Cairo country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06315465 id: AIIMSA00647 briefTitle: Efficacy of MAD as add-on Therapy in Comparison With Standard of Care in Children With ASD overallStatus: NOT_YET_RECRUITING date: 2024-03-20 date: 2026-01-01 date: 2026-01-01 date: 2024-03-18 date: 2024-03-18 name: All India Institute of Medical Sciences, New Delhi class: OTHER briefSummary: In general ketogenic diet is a recognized as an efficient non pharmacological treatment for children with refractory epilepsy. However, in the last decade, it has been tried for many neurological disorders in children including ASD, neurodegenerative disorders.
Studies have shown that KD also helps in improvement of cognition, social skills, language function, and stereotypies. There is a limited number of reports of improvements after KD treatment, was insufficient evidence to attest the practicability of the KD as a treatment for ASD, but it is still a good indicator that this diet is a promising therapeutic option for this disorder. There are no major RCT's, hence raises concerns about the reliability and generalizability of findings. Majority of studies have used combined ketogenic diet therapy rather than single diet therapy and not many studies have compared add-on dietary intervention with standard of care. When compared to classic KD diet Modified Atkin's Diet is less restrictive, more palatable, more feasible and early response can be achieved. In summary, the rationale for conducting this study lies in the importance of add on dietary therapy in form of Modified Atkin's Diet along with standard of care for improvement of behavioral symptoms in children with ASD aged 3-8 years.
This study aims to provide valuable insights that it can improve behavioral symptoms in ASD, early and ultimately improve the developmental outcomes in these children. conditions: Modified Atkins Diet conditions: Autism Spectrum Disorder conditions: Standard of Care studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Open Label Randomized Controlled Trial primaryPurpose: TREATMENT masking: NONE count: 80 type: ESTIMATED name: Modified Atkin's Diet with standard of care name: Standard of Care measure: To evaluate the efficacy of add-on Modified Atkin's Diet therapy with standard of care as compared to standard of care alone in children with Autism Spectrum Disorder aged 3-8 years measure: To evaluate the efficacy of add-on Modified Atkin's Diet therapy with standard of care as compared to standard of care alone in children with Autism Spectrum Disorder aged 3-8 years measure: To compare the change in the cognitive ability as measured by Developmental Quotient(DQ)in children receiving Modified Atkin's Diet with standard of care vs standard of care alone in children with Autism Spectrum disorder aged 3-8 years. measure: To compare the change in the cognitive ability as measured by Social Quotient(SQ)in children receiving Modified Atkin's Diet with standard of care vs standard of care alone in children with Autism Spectrum disorder aged 3-8 years. measure: To compare the change in the cognitive ability as measured by Intelligence Quotient(IQ)in children receiving Modified Atkin's Diet with standard of care vs standard of care alone in children with Autism Spectrum disorder aged 3-8 years. measure: To compare the quantitative reduction in behavioral problems using Child Behavior Checklist (CBCL) in children receiving Modified Atkin's Diet with standard of care vs standard of care alone in children with Autism Spectrum Disorder aged 3-8 years. measure: To compare the change in sleep related problems using Children's Sleep Habit Questionnaire (CSHQ)children receiving Modified Atkin's Diet with standard of care vs standard of care alone in children with Autism Spectrum Disorder age measure: To compare the resting state fMRI findings in a subset of patients in the two arms measure: To assess the compliance in children with Autism Spectrum Disorder receiving add-on Modified Atkin's Diet with standard of care measure: To assess the adverse effect profile in children with Autism Spectrum Disorder receiving add-on Modified Atkin's Diet with standard of care sex: ALL minimumAge: 3 Years maximumAge: 8 Years stdAges: CHILD hasResults: False
nctId: NCT06315452 id: PremaVitaD briefTitle: FREQUENCY OF VITAMIN D DEFICIENCY IN PREMATURE NEWBORN BORN BEFORE 32 WEEKS AND/OR WITH A BIRTH WEIGHT UNDER 1500g acronym: PremaVitaD overallStatus: ACTIVE_NOT_RECRUITING date: 2022-02-01 date: 2024-02-01 date: 2024-06-01 date: 2024-03-18 date: 2024-03-18 name: Fondation Hôpital Saint-Joseph class: OTHER briefSummary: Vitamin D plays an important role in phosphocalcic metabolism and bone homeostasis in newborns. Premature newborns are at risk of vitamin D deficiency and may require supplementation. In this context, the French Society of Pediatrics (Société Française de Pédiatrie) recommends systematic vitamin D testing at 1 month.
The aim of this study was to determine the frequency of vitamin D deficiency in premature newborns. conditions: Vitamin D Deficiency studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 110 type: ACTUAL measure: Vitamine D deficiency frequency measure: vitamine D deficiency and maternal or feotal caracteristics measure: vitamine D deficiency and premature newborn comorbidities measure: effect of supplementation sex: ALL minimumAge: 1 Day maximumAge: 6 Months stdAges: CHILD facility: Hôpital Saint Joseph city: Paris zip: 75014 country: France lat: 48.85341 lon: 2.3488 hasResults: False
nctId: NCT06315439 id: Multi-RELAMI briefTitle: Digital Confocal Microscopy for Real-time Diagnosis of Pancreatic Solid Lesion acronym: Multi-RELAMI overallStatus: COMPLETED date: 2023-01-01 date: 2023-11-30 date: 2023-11-30 date: 2024-03-18 date: 2024-03-18 name: Campus Bio-Medico University class: OTHER briefSummary: Endoscopic ultrasound-guided (EUS) tissue acquisition is the current standard of care for the diagnosis of pancreatic solid lesions but it is burdened by a non-negligible risk of non-diagnostic or inconclusive results.
Ex-vivo fluorescence confocal laser microscopy (FCM) with MAVIG VivaScope® 2500M-G4 could allow real time assessment of adequacy and diagnosis of the sample. conditions: Pancreas Adenocarcinoma conditions: Endoscopic Ultrasound conditions: Digital Pathology studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 78 type: ACTUAL name: Endoscopic ultrasound fine needle biopsy measure: Diagnostic accuracy sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione Policlinico Campus Bio Medico city: Rome state: Roma zip: 00191 country: Italy lat: 41.89193 lon: 12.51133 hasResults: False
nctId: NCT06315426 id: GR1802-011 briefTitle: A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR). overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-10 date: 2024-12 date: 2024-03-18 date: 2024-03-21 name: Genrix (Shanghai) Biopharmaceutical Co., Ltd. class: INDUSTRY briefSummary: Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies. Bronchial asthma is associated with bronchial asthma in 40% of patients with AR, suggesting a comorbid feature of allergic disease. conditions: Allergic Rhinitis studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 90 type: ESTIMATED name: GR1802 injection name: Placebo measure: Change from Baseline in rTNSS( reflective total nasal symptom scores) measure: Change from Baseline in rTOSS( reflective total ocular symptom scores) measure: Change from Baseline in rTNSS measure: Mean change from baseline in iTNSS(instantaneous total nasal symptom scores) measure: Mean change from baseline in iTOSS(instantaneous total ocular symptom scores) measure: Change from baseline in VAS(Visual Analog Scale) score measure: Change from baseline in RQLQ(Rhinoconjunctivitis Quality of Life Questionnaire) scores measure: Adverse events (AEs) measure: Immunogenicity characteristics sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06315413 id: Composite plug vs d-PTFE briefTitle: Composite Plug vs d-PTFE Membrane in Socket Preservation overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-08-01 date: 2025-12-01 date: 2024-03-18 date: 2024-03-18 name: Cairo University class: OTHER briefSummary: The aim of the current study is to compare the effect socket sealing with flowable resin composite compared to dense polytetrafluoroethylene membrane after filling the extraction site with xenograft particles in terms of soft and hard tissue changes, procedural time, post operative pain, patients' satisfaction, and cost effectiveness. conditions: Alveolar Bone Loss studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 20 type: ESTIMATED name: Socket preservation using xenograft and composite plug name: Socket preservation using xenograft and intentionally exposed d-PTFE measure: Change in horizontal bone dimension measure: Change in Vertical bone dimension measure: Keratinized tissue thickness measure: Procedural time measure: Post-operative pain measure: Patient Satisfaction measure: Incidence of complications sex: ALL minimumAge: 20 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Faculty of oral and dental medicine, Cairo university city: Cairo zip: 4240310 country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06315387 id: GIB-01-01-2023 briefTitle: Safety, Tolerability and Pharmacokinetics of 4-MUST, Tablets, 128 mg (Valenta Pharm JSC) During Single and Multiple Oral Administration in Healthy Volunteers overallStatus: RECRUITING date: 2023-12-04 date: 2024-12-31 date: 2024-12-31 date: 2024-03-18 date: 2024-03-18 name: Valenta Pharm JSC class: INDUSTRY briefSummary: Study of safety, tolerability and pharmacokinetic parameters of different doses of 4-MUST, tablets, 128 mg (Valenta Pharm JSC) in healthy volunteers conditions: Cholecystitis studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: OTHER masking: NONE count: 42 type: ESTIMATED name: 4-MUST, 1 tablet name: 4-MUST, 2 tablets name: 4-MUST, 3 tablets measure: Pharmacokinetics - Cmax measure: Pharmacokinetics - tmax measure: Pharmacokinetics - AUC0-t measure: Pharmacokinetics - AUC0-inf measure: Pharmacokinetics - AUCextr measure: Pharmacokinetics - t1/2 measure: Pharmacokinetics - kel measure: Pharmacokinetics - MRT measure: Pharmacokinetics - Vd measure: Pharmacokinetics - CL measure: Pharmacokinetics - number of terminal timepoints measure: Adverse event type measure: Adverse event frequency measure: Adverse event severety measure: Drop-outs associated with adverse events sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Limited Liability Company "Medical Center Eco-Safety" status: RECRUITING city: St. Petersburg zip: 19119 country: Russian Federation name: Vasiliy Vasilyuk, MD,PhD, Prof. role: CONTACT phone: +7 (812) 500-52-03 phoneExt: 5001 email: vasilyuk_vb@ecosafety.ru lat: 59.93863 lon: 30.31413 hasResults: False
nctId: NCT06315374 id: FJUH112267 briefTitle: 3D-Printed Aerosolized Medication Delivery Assist Device in Patients With Chronic Respiratory Diseases overallStatus: NOT_YET_RECRUITING date: 2024-03-30 date: 2024-07-31 date: 2024-07-31 date: 2024-03-18 date: 2024-03-19 name: Fu Jen Catholic University class: OTHER briefSummary: The purpose of this study is to investigate the auxiliary benefits of three-dimensional printed activating assistive devices for soft-mist inhaler on patients' utilization habit. conditions: Chronic Pulmonary Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: OTHER masking: NONE count: 60 type: ESTIMATED name: Use soft mist inhaler name: Use soft mist inhaler with a 3D assistive device measure: satisfaction survey sex: ALL minimumAge: 45 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fu Jen Catholic University Hospital, Fu Jen Catholic University city: New Taipei City zip: 24352 country: Taiwan name: Ke-Yun Chao, PhD role: CONTACT phone: +886-905-301-879 email: ck_qq@hotmail.com name: Ke-Yun Chao, PhD role: PRINCIPAL_INVESTIGATOR lat: 25.01111 lon: 121.44583 hasResults: False
nctId: NCT06315361 id: 2445 briefTitle: DIAbetes and NAFLD acronym: DIANA overallStatus: ACTIVE_NOT_RECRUITING date: 2019-05-20 date: 2035-12-31 date: 2035-12-31 date: 2024-03-18 date: 2024-03-18 name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS class: OTHER briefSummary: Non-alcoholic hepatic steatosis (NAFLD) is characterised by the excessive accumulation of triglycerides in the liver and is often associated, in the absence of significant alcohol consumption, with insulin resistance and metabolic syndrome with which it shares the most frequent clinical manifestations (hypertension, dyslipidaemia, visceral adiposity, glucose intolerance). Due to the pandemic spread of obesity and diabetes and by virtue of better control of viral hepatitis, NAFLD is the most common cause of liver damage in Western countries with a prevalence of around 20-30% of the general population.
Individuals with diabetes are, in fact, those at greatest risk of developing the clinical sequelae of NAFLD and often do not receive adequate hepatological support and a correct hepatic pathology. In fact, it has been documented in the literature that the presence of diabetes increases the severity of liver damage, bringing the risk of NASH up to 80% and increasing the risk of significant fibrosis to 30-40% of subjects with hepatic steatosis as well as representing an independent predictor for significant fibrosis. Lastly, the increased risk of hepatocarcinoma in subjects with diabetes and NAFLD should not be overlooked, as documented by our group and confirmed in a large Italian case series.
Therefore, the possibility of applying the non-invasive fibrosis scores currently available for NAFLD on a large scale, in a population at high risk of progressive liver disease, would make it possible to characterise (a) the true epidemiology of significant fibrosis (F3 or higher); (b) allow primary prevention actions to be carried out by optimising the use of resources or by identifying subjects at greater risk of damage progression; (c) understand, in cases with a long history of disease the true prevalence of clinical outcomes; (d) understand the epidemiology of comorbidities and polypharmacy as a function of significant fibrosis. conditions: NAFLD conditions: Diabetes conditions: NASH conditions: Fibrosis, Liver conditions: Cirrhosis, Liver conditions: Liver Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 600 type: ESTIMATED measure: Prevalence of significant fibrosis by non invasive tests measure: Identification of MALO (major liver outcomes) measure: Identification of MACE sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: UOSD Diabetologia, Catholic University of Rome, Fondazione Policlinico Gemelli IRCCS city: Roma state: Rome/lazio/italy zip: 00168 country: Italy lat: 41.89193 lon: 12.51133 hasResults: False